Tolerability of  -Blockade With Doxazosin as a Therapeutic Option for Symptomatic Benign Prostatic Hyperplasia in the Elderly Patient: A Pooled Analysis of Seven Double-Blind, Placebo-Controlled Studies

Kaplan, Steven A.; D'Alisera, Patricia Meade

doi:10.1093/gerona/53a.3.m201

Cited by 24 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, several findings question this conclusion. Doxazosin and terazosin lower blood pressure to a greater extent in hypertensive compared with normotensive patients with LUTS, but their incidence of adverse effects appears to be similar [46]. A slow-release formulation of doxazosin similarly was effective in blood pressure and LUTS reduction as the standard formulation, but had an improved tolerability [47].…”

Section: Adverse Effects Of α-Adrenoceptor Antagonistsmentioning

confidence: 98%

Mode of action of α-adrenoceptor antagonists in the treatment of lower urinary tract symptoms

Andersson

2005

Current Prostate Reports

View full text Add to dashboard Cite

Section: Adverse Effects Of α-Adrenoceptor Antagonistsmentioning

confidence: 98%

Mode of action of α-adrenoceptor antagonists in the treatment of lower urinary tract symptoms

Andersson

2005

Current Prostate Reports

View full text Add to dashboard Cite

“…The analyzed pooled safety data from seven completed multicenter, double-blind, placebo-controlled studies of doxazosin treatment in patients with BPH, after stratification by age and blood pressure status, 36 included 315 normotensive patients aged o65 y and 320 normotensive patients aged X65 y. Neither of these normotensive age groups showed clinically important reductions in mean blood pressure during treatment with doxazosin.…”

Section: Effects On Blood Pressure In Normotensive Patients With Bphmentioning

confidence: 99%

Clinical ease of using doxazosin in BPH patients with and without hypertension

Steers

Kirby

2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline. In patients with BPH and uncontrolled hypertension, despite treatment with other antihypertensive drugs, the addition of doxazosin resulted in improved control with significant reductions in BP. The new formulation, doxazosin gastrointestinal therapeutic system (GITS), is initiated at a therapeutic dose, simplifying dose titration. Based on its efficacy and pharmacokinetic and tolerability profiles, doxazosin GITS is an effective and welltolerated treatment for normotensive and hypertensive patients with BPH. Prostate Cancer and Prostatic Diseases (2005) 8, 152-157.

show abstract

“…In that study [60], alfuzosin produced a more marked blood pressure reduction than tamsulosin, but both drugs had a very similar adverse event pro®le, which was similar to that of placebo. Whereas doxazosin [61,62] and terazosin [63] lower blood pressure to a greater extent in hypertensive than in normotensive patients with LUTS, their incidence of side-effects is similar in both normotensive and hypertensive patients [64]. More recently, both the slow-release formulations of doxazosin and alfuzosin have been shown to be similarly effective in both blood pressure and LUTS reduction as the standard formulation, but with improved tolerability [65,66 . ].…”

Section: Do Alpha Adrenoceptor Antagonists Produce Apoptosis?mentioning

confidence: 99%

Alpha adrenoceptor antagonists in the year 2000: is there anything new?

Chapple

2001

Current Opinion in Urology

View full text Add to dashboard Cite

Selective alpha1-adrenergic blockade is now a well accepted and widely used therapeutic treatment for patients presenting with symptomatic bladder outlet obstruction thought to be associated with benign prostatic hyperplasia. This review summarizes the recent developments in this field relating to the subject of receptor subtype selectivity and the potential relevance of this to clinical usefulness of existing drug therapy. Whilst a number of unanswered questions remain as to the exact mechanisms of both drug action and side-effect profile, nevertheless it is clear that existing clinically available alpha1-antagonists provide a safe, effective and generally well tolerated therapy for patients with lower urinary tract symptoms thought to be associated with benign prostatic obstruction. The implications of the ALLHAT study are discussed.

show abstract

Tolerability of -Blockade With Doxazosin as a Therapeutic Option for Symptomatic Benign Prostatic Hyperplasia in the Elderly Patient: A Pooled Analysis of Seven Double-Blind, Placebo-Controlled Studies

Abstract: Background. Benign prostatic hyperplasia (BPH) is a common disorder in males, and its incidence increases with age. Safety results from trials with doxazosin therapy in elderly patients were collated and described.

Cited by 24 publications

References 28 publications

Mode of action of α-adrenoceptor antagonists in the treatment of lower urinary tract symptoms

Mode of action of α-adrenoceptor antagonists in the treatment of lower urinary tract symptoms

Clinical ease of using doxazosin in BPH patients with and without hypertension

Alpha adrenoceptor antagonists in the year 2000: is there anything new?

Contact Info

Product

Resources

About